Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 3, 2005, Pages 296-300

  Van Leth, Frank ^a   Huisamen, Casper B ^b   Badaro, Roberto ^c   Vandercam, Bernard ^d   De Wet, Joss ^e   Montaner, Julio S G ^e   Hall, David B ^f   Wit, Ferdinand W N M ^a   Lange, Joep M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Moltena Road Practice ^*  (South Africa)

^c Professor Edgard Santos University Hospital   (Brazil)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

2NN; Efavirenz; HIV 1; Nevirapine; Nonnucleoside reverse transcriptase inhibitor; Randomized clinical trial; Viral dynamics

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LAMIVUDINE; MALE; NEVIRAPINE; OXAZINES; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; STAVUDINE; TREATMENT OUTCOME;

EID: 14744289438     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Louie M, Hogan C, Di Mascio M, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis. 2003;187:896-900.
2. Perelson AS, Nelson PW. Mathematical analysis of HIV-1 dynamics in vivo. Siam Review. 1999;41:3-44.
3. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
4. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
5. Cozzi Lepri A, Miller V, Phillips AN, et al. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS. 2001;15:47-54.
6. Raboud JM, Rae S, Montaner JS. Predicting HIV RNA virologic outcome at 52 weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups. J Acquir Immune Defic Syndr. 2000;24:433-439.
7. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
8. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863-868.
9. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet. 2001;358:1760-1765.
10. Mittler J, Essunger P, Yuen GJ, et al. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother. 2001;45:1438-1443.
11. Wu H, Mellors J, Ruan P, et al. Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. J Acquir Immune Defic Syndr. 2003;33:557-563.
12. Wu H, Kuritzkes DR, McClemon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999;179:799-807.
13. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263.
14. King RW, Klabe RM, Reid CD, et al. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother. 2002;46:1640-1646.
15. Kappelhoff BS, Rosing H, Huitema AD, et al. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;792:353-362.
16. Beal S, Sheiner L. NONNMEM User's Guides. NONMEM Project Group. San Francisco: University of California at San Francisco; 1998.
17. Centers for Disease Control and Prevention. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
18. Notermans DW, Goudsmit J, Danner SA, et al. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998;12:1483-1490.
19. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-191.
20. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
21. Nowak MA, Bonhoeffer S, Loveday C, et al. HIV results in the frame. Results confirmed. Nature. 1995;375:193.
22. Wu H, Ding AA, De Gruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS. 1999;13:429-430.
23. Hall D, van Leth F, Scherer J. Genotypic analysis of reverse transcriptase in treatment naive HIV-1 patients treated with lamivudine, stavudine, nevirapine and/or efavirenz. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004.
24. de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis. 1997;175:966-970.
25. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171:537-545.